BPC-157 is one of the few research peptides that can be administered both orally and via injection with demonstrated activity through either route. This is unusual for peptides, which are typically degraded in the stomach. Understanding the differences between oral and injectable BPC-157 is critical for selecting the appropriate protocol.
Why BPC-157 Survives Oral Administration
Most peptides are broken down by stomach acid and digestive enzymes before reaching the bloodstream. BPC-157 is an exception. It was originally isolated from human gastric juice and demonstrates remarkable acid stability (Sikiric et al., 2018). This stability allows it to pass through the stomach intact and exert local effects on the gastrointestinal lining.
Rodent studies have shown oral BPC-157 is effective for treating NSAID-induced gastric lesions (Sikiric et al., 2006), alcohol-induced gut damage, and models of inflammatory bowel disease. The peptide appears to act locally on the gut mucosa and also reaches systemic circulation, though at lower concentrations than subcutaneous injection.
Bioavailability Comparison
| Parameter | Subcutaneous Injection | Oral Capsule |
|---|---|---|
| Estimated bioavailability | ~90-95% | ~20-40% (estimated) |
| Onset of action | Minutes | 30-60 minutes |
| Peak concentration | 15-30 minutes | 60-90 minutes |
| Best suited for | Systemic healing (tendons, muscles, joints) | Gut healing, gastric protection, convenience |
| Typical dose | Lower material requirement | Higher material requirement |
| Requires reconstitution | Yes | No |
Exact oral bioavailability in humans has not been established in published clinical trials. The 20-40% estimate is derived from pharmacokinetic modelling and rodent absorption data. The higher oral dose range accounts for first-pass hepatic metabolism and incomplete GI absorption.
When to Choose Oral BPC-157
- Gut health goals: Intestinal permeability, gastric ulcers, IBD symptom management, leaky gut protocols
- Convenience: No needles, no reconstitution, no cold storage required for capsules
- Compliance: Easier to maintain daily dosing without injection supplies
- First-time researchers: Lower barrier to entry for those uncomfortable with injections
When to Choose Injectable BPC-157
- Musculoskeletal injury: Tendon, ligament, and muscle healing where systemic bioavailability matters
- Local targeting: Injection near the injury site for higher local peptide concentration
- Stacking protocols: When combining with other injectable peptides like TB-500
- Cost efficiency: Lower dose required means vials last longer
Can You Combine Both Routes?
Some published work uses both oral and parenteral routes in the same model, targeting gut and systemic endpoints together. There is no published evidence of adverse interactions between the two routes. Dosing and administration guidance is outside the scope of research-use-only material.
UK Market: Oral BPC-157 Supplements
Several UK-based supplement companies now sell oral BPC-157 in capsule form, typically at 250-500 mcg per capsule. These are marketed as food supplements under current UK regulations. The regulatory landscape is evolving; the MHRA has not issued specific guidance on BPC-157 as of March 2026.
When evaluating oral BPC-157 products, key quality indicators include third-party COA (Certificate of Analysis) from an independent lab, HPLC purity testing above 99%, and proper capsule formulation to protect the peptide through the stomach.
Practical Dosing Reference
For a full dosing breakdown including reconstitution instructions and syringe diagrams, see our BPC-157 dosage guide and reconstitution calculator.
Key References
- Sikiric, P. et al. (2018). "Brain-gut axis and pentadecapeptide BPC 157." Current Neuropharmacology, 16(5), 512-533.
- Sikiric, P. et al. (2006). "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design, 12(30), 4051-4067.
- Seiwerth, S. et al. (2014). "BPC 157 and standard angiogenic growth factors." Life Sciences, 97(2), 183-189.